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SObjective: Five-year survival after the diagnosis of non–small cell lung cancer is the most common benchmark
used to evaluate long-term survival. Data on survival beyond 5 years are sparse. We sought to elucidate variables
affecting 10- to 18-year survival.
Methods:A total of 31,206 patients alive at least 5 years after diagnosis of non–small cell lung cancer whowere
registered in the Surveillance, Epidemiology, and End Results database from 1988 to 2001 were examined.
Primary end points were disease-specific survival and overall survival. Survival analysis was performed with
Kaplan–Meier estimates, multivariable Cox proportional hazards regression, and competing risk models.
Results: Overall survival at 10, 15, and 18 years was 55.4%, 33.1%, and 24.3%, respectively. Disease-specific
survival at 10, 15, and 18 yearswas 76.6%, 65.4%, and 59.4%, respectively. Inmultivariable regression analysis,
squamous cell cancers had a disease-specific survival advantage (hazard ratio, 0.88; P<.0001) but an overall
survival disadvantage (hazard ratio, 1.082;P¼ .0002) comparedwith adenocarcinoma. Pneumonectomy (hazard
ratio, 0.44) and lobectomy (hazard ratio, 0.474) had improved disease-specific survival comparedwith no surgery
(P< .0001). Left-sided tumors (hazard ratio, 0.723; P ¼ .036) and node-negative cancers (hazard ratio,
0.562; P<.001) also had a better disease-specific survival and, to a lesser extent, overall survival advantage.
Conclusions: Five-year survivors of non–small cell lung cancer have a persistent risk of death from lung cancer
up to 18 years from diagnosis. More than one half of all deaths in 5-year survivors are related to lung cancer. In
multivariable regression analysis, age, node-negative disease, and lobar or greater resection were strong predic-
tors of long-term survival (ie, 10–18 years). (J Thorac Cardiovasc Surg 2012;143:1307-13)Non–small cell lung cancer (NSCLC) is one of the most
common noncutaneous cancers, with more than 222,520
new cases in 2010.1 Only 15% of patients with newly diag-
nosed lung cancer will be expected to survive 5 years from
their diagnosis.2 Five-year survival is the most commonly
used benchmark for long-term survival in NSCLC and
has, at times, been equated with cure.3 Others have claimed
that 5 years is inadequate and have proposed 10 years as
‘‘adequate proof of cure.’’4 Prospective long-term cancer
studies are costly, and data beyond 5 years are scarce.
Prior studies have suggested equivalent 5- and 10-year
survivals. The International Early Lung Cancer Screening
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The Journal of Thoracic and Carand 484 patients with lung cancer showed that the estimated
5- and 10-year survivals were nearly identical in this group
of mostly patients with stage I lung cancer.5 This screened
population was obviously a highly selected group with early
lung cancers. In 1999, a report fromMemorial Sloan Ketter-
ing reviewed 686 long-term survivors who had undergone
curative resection between 1973 and 1989. The estimated
overall 10-year survival was 93% for patients with stage I
lung cancer and 92% for patients with stage II and III
lung caner. In this study of 686 patients, however, no vari-
ables (including age, sex, histology, or stage) were useful
in predicting late recurrence.6
We sought to examine long-term survival in NSCLC us-
ing the Surveillance, Epidemiology, and End Results
(SEER) database of the National Cancer Institute. This da-
tabase represents a cross-section of socioeconomic and geo-
graphic populations across the United States and allows for
analysis of individual variables, stage, and treatment factors
on long-term survival. We sought to further clarify long-
term survival and examine variables affecting 10-, 15-,
and 18-year survival.MATERIALS AND METHODS
The study population was patients with NSCLC from the SEER data-
base of the National Cancer Institute from 1988 to 2001 with follow-updiovascular Surgery c Volume 143, Number 6 1307
Abbreviations and Acronyms
DSS ¼ disease-specific survival
HR ¼ hazard ratio
NSCLC ¼ non–small cell lung cancer
OS ¼ overall survival
SEER ¼ Surveillance, Epidemiology, and End
Results
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Sof at least 5 years (through 2006 at the latest). The SEER database is
a multi-institutional, community-based cancer registry from 12
population-based cancer registries in the United States, containing demo-
graphics, clinical, pathologic, and survival data. An exemption for institu-
tional review board review and need for individual patient consent was
granted by the Case Western Institutional Review Board, Exempt-
CC010-2008.
Data regarding patient age, year of diagnosis, patient gender and race,
tumor side, histology, size, nodal involvement, regional and distant exten-
sion/metastases, stage, overall survival (OS) (in months), and cause of
death were collected. Tumor size was categorized as less than 3 cm or
greater than or equal to 3 cm for univariate analysis.
The age of the patient was collected at the time of diagnosis or initial
treatment. The histology of tumors was classified into 6 categories based
on the International Classification of Diseases for Oncology7: squamous
cell carcinomas (8050–8123, 8562), adenocarcinomas (8140, 8141,
8250–8323, 8480–8550, 8572), large cell carcinomas (8012–8031), ad-
enosquamous carcinomas (8560, 8570), unknown histology (8000, 8010,
and missing values), and other tumors that includes spindle-cell carcino-
mas, mucoepidermoid malignancies, and carcinoid tumors. Surgery type
was categorized as pneumonectomy, lobectomy (with or without nodal dis-
section), sublobectomy resection (wedge resection or segmentectomy), or
no surgery. Excisional biopsies and other surgeries performed without cu-
rative intent were categorized in the ‘‘no surgery’’ group.TABLE 1. Patient and cancer characteristics at diagnosis or initial treatm
Factor N (%)
Male 15,118 (48.45)
Histology
Adeno 15,876 (50.87)
Adenosquamous 716 (2.29)
Large cell 1980 (6.34)
Other 2373 (7.60)
Squamous 8098 (25.95)
Unknown 2163 (6.93)
Stage
IA/IB 11,030/10,659 (69.50)
IIA/IIB 829/775 (5.14)
IIIA/IIIB 2210/4206 (20.56)
IV 1497 (4.80)
T stage
T1 12,985 (41.61)
T2 14,352 (45.99)
T3 1157 (3.71)
T4 2146 (6.88)
Unknown 566 (1.81)
M stage
M0 29,709 (95.20)
M1 1497 (4.80)
1308 The Journal of Thoracic and Cardiovascular SurA total of 51,072 patients aged more than 18 years who had survived 60
months or more diagnosed with NSCLCwere located. A total of 34,572 pa-
tients were diagnosed on or after 1988. A total of 34,510 patients remained
after the exclusion of in situ disease. A total of 31,206 patients remained for
analysis after exclusion of those patients for whom type of surgery or ab-
sence of surgery was not documented.
Patients alive (including those with disease) at least 5 years after diag-
nosis were included. Cause of death was determined by the SEER database
collection of hospital and death certificate information and stated using the
International Classification of Diseases, 10th Revision.8 OS was measured
from the date of diagnosis to the date of death and censored at the date of
last follow-up for survivors. Disease-specific survival (DSS) was measured
from the date of diagnosis to the date of death from lung cancer and cen-
sored at the date of last follow-up for survivors or the date a patient died
of causes other than lung cancer. The determination of a lung cancer versus
non–lung cancer cause of death was determined in order of availability by
state health department records, other sources such as the National Death
Index or state data exchange, and coding from a trained International Clas-
sification of Diseases, 10th Revision expert for registry data entry.
Probability of OS and DSS was estimated using the Kaplan–Meier
method for categoric variables in the univariate analysis; the difference be-
tween/among groups was examined using the log-rank test. The factors that
were significant in predicting OS and DSS in the univariate analysis were
further examined by Cox proportional hazard regression9 and competing
risk models,10,11 respectively. Multivariable regression models that
include the variables of age (in years), gender, histology, tumor site,
TNM status, and surgery type performed were done for OS and DSS. All
tests were 2-sided. Significant differences in DSS and OS for different T
and N status in the univariate analysis were determined by the log-rank
test followed by the Tukey method for multiple comparisons.RESULTS
A total of 31,206 patients met the inclusion criteria for
this study with a median age of 66 years (range, 18–103
years). The patient and cancer characteristics at diagnosisent
Factor N (%)
Side of tumor
0 (not paired site) 5 (0.02)
1 (right) 18,004 (57.69)
2 (left) 12,936 (41.45)
3 (only 1 side) 29 (0.09)
4 (bilateral) 93 (0.30)
9 (paired site) 139 (0.45)
Surgery type
Lobectomy 21,423 (68.65)
No surgery 4679 (14.99)
Pneumonectomy 2203 (7.06)
Sublobectomy 2901 (9.30)
Race
White 26,601 (85.24)
Black 2668 (8.55)
Other 1937 (6.21)
N stage
N0 23,847 (76.42)
N1 3178 (10.18)
N2 2924 (9.37)
N3 415 (1.33)
Unknown 842 (2.70)
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FIGURE 1. Graphs of DSS (top red line) and OS (bottom black line) in
patients with NSCLC surviving more than 5 years. CL, Confidence limit;
DSS, disease-specific survival; OS, overall survival.
TABLE 2. Analysis of overall survival (%) by Kaplan–Meier method
(univariate)
n
At 5
y
At 10
y
At 15
y
At 18
y
P
value
Whole group 31,206 99 55.4 33.1 24.3
Age
<60 y 9211 99.4 71.8 54.6 46
60–70 y 12,365 98.7 55 30.6 20 <.0001
>70 y 9630 98.6 39.6 13.6 6.5
Tumor size
<3 cm 15,091 99.1 58.2 36.3 27.4 <.0001
3 cm 13,631 98.8 54 30.8 21.3
Sex
Male 15,118 98.9 52.7 29.7 20.7 <.0001
Female 16,088 98.9 58.1 36.7 28.2
Site of tumor
1 (right) 18,004 98.9 56.2 34.3 26.4
2 (left) 12,936 98.8 54.5 31.5 21.5 <.0001
4, 9 (bilateral,
paired)
232 98.3 43.9 26.7 26.7
Histology
Adeno 15,876 98.9 56 34.4 25.3
Adenosquamous 716 99 55 30.6 22.9
Large cell 1980 99 56.6 32.4 24.6 <.0001
Other 2373 99.7 80.4 64.1 58.9
Squamous 8098 98.9 49.4 24.7 15.6
Unknown 2163 97.5 44.6 24.7 14.9
Surgery type
Lobectomy 21,423 99.2 59.7 36.5 26.9
No surgery 4679 97.6 36.9 18.1 11.2 <.0001
Pneumonectomy 2203 99.1 59.5 36.4 28.7
Sublobectomy 2901 98.6 47.6 25.8 19.1
T stage
T1 12,985 99.0 58.0 36.0 26.7 <.0001
T2 14,352 98.9 54.9 32.0 23.0
T3 1157 98.4 53.0 32.0 23.2
T4 2146 98.1 47.6 25.4 19.9
Tunk 566 98.1 40.4 20.6 18.3
N stage
N0 23,847 99.0 57.8 35.1 26.1 <.0001
N1 3178 98.8 52.1 28.7 19.7
N2 2924 98.1 44.3 24.5 16.5
N3 415 99.0 46.6 30.1 13.4
Nunk 842 98.0 39.8 21.6 18.1
M stage
M0 29,709 98.9 56.1 33.5 24.6 <.0001
M1 1497 98.1 40.7 22.0 16.2
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Sor initial treatment are summarized in Table 1. Seventy pa-
tients (69.5%) had stage IA/IB disease. Surgery was per-
formed on most patients; 4679 patients (15% of the
cohort) had no curative surgery attempted. OS and DSS
curves are shown in Figure 1.
OS data analysis by the Kaplan–Meier method for single
variables is shown in Table 2. Data are shown for survival at
10, 15, and 18 years (the longest survival possible given the
data range of 1988–2006) from the time of diagnosis. The
entire group of 31,206 patients had 55.4% survival at 10
years, 33.1% survival at 15 years, and 24.3% survival at
18 years. Significant differences can be seen in OS accord-
ing to age, gender, tumor size, nodal status, presence of met-
astatic disease, tumor side, histology, stage, and type of
curative surgery. The results from multivariable Cox pro-
portional hazard for OS are detailed in Table 3. The differ-
ences between T2 and T3 and T2 and T4 were not
statistically significant (P>.05). Nodal stage had a signifi-
cant impact on OS: The hazard ratio (HR) was 1.325 for N1
versus N0, 1.254 for N2 versus N0, and 1.116 for N3 versus
N0. Moreover, there were statistically significant differ-
ences in OS between each pair of nodal stage (ie, N1 vs
N2, N1 vs N3, and N2 vs N3) (with a multiple comparisons
adjusted P<.004).
For DSS, 300 patients were excluded because there was
no cause of death listed in the database. Patients who
were alive at the time of censoring or the end of data collec-
tion were included. Data for the Kaplan–Meier univariate
DSS analysis are shown in Table 4.
Univariate analysis of the whole group of 30,906 patients
had a 10-year DSS of 76.6%, a 15-year DSS of 65.4%, and
an 18-year DSS of 59.4%. When analyzed by age group,
there was a statistically significant difference (P<.0001)
among the 3 groups: those aged less than 60 years (73%
DSS), those aged 60 to 70 years (61.6% DSS), and those
aged 70 years or more (60.8% DSS) at 15 years. In contrast
with the OS results, those aged 60 70 years and more than
70 years had similar DSS.The Journal of Thoracic and CarGender, tumor size, TNM status, and histology were all
statistically significant in predicting DSS. The type of sur-
gery performed for curative intent also showed statistical
significance (P<.0001) when predicting DSS. At 15 years,
patients who received a pneumonectomy had 68.8% DSS,
patients who received a lobectomy had 69.2% DSS, pa-
tients who received a sublobar resection had a 61.0%
DSS, and patients who did not have a surgical procedure
for curative intent had a 43.8% DSS (Figure 2).diovascular Surgery c Volume 143, Number 6 1309
TABLE 3. Analysis of overall survival by Cox proportional hazard model (multivariable regression)
Factor Parameter estimate SE HR 95% HR confidence limit P value
Age (per year increase) 0.044 0.001 1.045 (1.043–1.047) <.0001
Sex (male vs female) 0.154 0.018 1.166 (1.125–1.209) <.0001
Histology
Other vs adeno 0.704 0.049 0.494 (0.449–0.544) <.0001
Adenosquamous vs adeno 0.006 0.059 1.006 (0.896–1.129) .921
Large cell vs adeo 0.065 0.036 0.938 (0.873–1.007) .077
Squamous vs adeno 0.079 0.021 1.082 (1.038–1.128) .0002
Unknown vs adeno 0.01 0.039 0.991 (0.918–1.069) .808
Surgery type
Pneumonectomy vs no surgery 0.58 0.046 0.560 (0.511–0.613) <.0001
Sublobectomy vs no surgery 0.235 0.041 0.791 (0.730–0.856) <.0001
Lobectomy vs no surgery 0.558 0.032 0.572 (0.537–0.610) <.0001
Site of tumor
4, 9 (bilateral, paired) vs right 0.021 0.018 1.022 (0.986–1.058) .235
Left vs right 0.202 0.110 0.817 (0.658–1.014) .067
T stage
T2 vs T1 0.053 0.020 1.055 (1.015–1.096) .007
T3 vs T1 0.115 0.049 1.122 (1.020–1.234) .018
T4 vs T1 0.096 0.040 1.101 (1.017–1.192) .018
Tunk vs T1 0.025 0.082 0.975 (0.830–1.146) .760
N stage
N1 vs N0 0.282 0.029 1.325 (1.252–1.404) <.0001
N2 vs N0 0.226 0.034 1.254 (1.173–1.340) <.0001
N3 vs N0 0.110 0.084 1.116 (0.947–1.316) .189
Nunk vs N0 0.007 0.062 0.993 (0.879–1.122) .912
M stage
M1 vs M0 0.188 0.052 1.207 (1.089–1.337) .0003
Race
Black vs white 0.093 0.031 1.097 (1.032–1.167) .003
Other vs white 0.213 0.039 0.808 (0.749–0.873) <.0001
SE, Standard error; HR, hazard ratio.
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STable 5 shows the results of multivariable competing risk
model for DSS. The disease-specific HR for each additional
year of age was 1.021 (P<.0001). Male gender and adeno-
carcinoma histology had worse DSS. Left-sided tumors had
a statistically significant DSS advantage compared with
right-sided tumors (HR, 0.723; P ¼ .036). When compared
with not receiving surgery for curative intent, multivariable
analysis showed a DSS benefit for pneumonectomy (HR,
0.440), lobectomy (HR, 0.474), and sublobectomy (HR,
0.710) (all P<.0001).
Advanced tumor stages (T2, T3, T4) showed significantly
worse DSS compared with T1 stage tumors. Node-positive
patients showed significantly worse DSS than node-
negative patients (N1 vs N0, HR 1.607; N2 vs N0, HR
1.464; and N3 vs N0, HR 1.339). Moreover, the differences
in survival between each nodal stagewas statistically signif-
icant (N1 vs N2, N2 vs N3, and N1 vs N3, all P<.0001).
When a separate multivariable analysis was performed
grouping all nodal patients together as node positive (N1
or N2 or N3) and comparing with N0 patients, the HR
was 1.293 for OS (P < .0001) and 1.538 for DSS
(P<.0001).1310 The Journal of Thoracic and Cardiovascular SurDISCUSSION
This SEER review of 5-year NSCLC survivors reveals
that 5-year survival does not equal cure from lung cancer
and that approximately half of the deaths in 5-year survivors
are categorized as due to lung cancer.
There are several important limitations to this study.
First, although the SEER database is broad, the accuracy
of the submitted data is dependent on submissions by indi-
vidual practitioners.12 The categorization of cause of death
as lung cancer or non–lung cancer-related may not always
be clear. Death from neutropenic infection related to a che-
motherapy treatment would most likely be categorized as
lung cancer related. Death from pneumonia 6 years after
pneumonectomy would likely not be attributed to lung
cancer, although it depends on the judgment of the individ-
ual filling out the death certificate. Second, the SEER da-
tabase does not contain data regarding chemotherapy,
and radiation data were excluded from the analysis be-
cause it was complete for only 10% of patients. Third,
DSS in the SEER database does not distinguish between
death from the original tumor and death from a new, sep-
arate lung primary. It has been estimated that patients withgery c June 2012
TABLE 4. Analysis of disease-specific survival (%) by Kaplan–Meier
method (univariate)
n At 5 y At 10 y At 15 y At 18 y
P
value
Whole group 30,906 99.3 76.6 65.4 59.4
Age
<60 y 9136 99.6 82.2 73 67.9
60–70 y 12,232 99.2 74.8 61.6 54.2 <.0001
>70 y 9538 99.3 72.7 60.8 54.9
Tumor size
<3 cm 14,963 99.5 79.2 69.2 63.8 <.0001
3 cm 13,493 99.2 75.2 62.5 55.5
Sex
Male 14,962 99.4 75.8 64 57.8 .0005
Female 15,944 99.3 77.4 66.7 61
Site of tumor
1 (right) 17,835 99.4 77 66 60.3
2 (left) 12,807 99.3 76.2 64.6 58.2 .01
4, 9 (bilateral,
paired)
230 99.1 66.9 58.7
Histology
Adeno 15,723 99.3 74.9 63.7 56.5
Adenosquamous 709 99.7 77.8 62.9 62.9
Large cell 1953 99.4 77 63.4 57.9 <.0001
Other 2361 99.9 95 92.4 91.9
Squamous 8020 99.5 75.6 61.9 55.7
Unknown 2140 98.4 69.1 57.6 51.3
Surgery type
Lobectomy 21,227 99.5 80.2 69.2 63.4
No surgery 4611 98.5 58.3 43.8 35.7 <.0001
Pneumonectomy 2191 99.5 79.7 68.8 64.3
Sublobectomy 2877 99.4 72 61 52.7
T stage
T1 12,880 99.5 79.3 69.3 63.0 <.0001
T2 14,198 99.3 76.4 64.5 58.4
T3 1145 99.1 71.4 59.4 58.1
T4 2125 98.7 67.1 53.6 46.4
Tunk 558 98.6 62.5 45.1
N stage
N0 23,627 99.0 79.7 68.9 63.1 <.0001
N1 3153 99.0 70.9 58.8 52.5
N2 2880 98.6 62.2 50.4 40.7
N3 414 99.5 62.9 50.5 44.9
Nunk 832 98.9 62.7 43.7 40.3
M stage
M0 29,425 99.4 77.3 66.2 60.1 <.0001
M1 1481 98.6 60.1 45.2 41.4
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Sresected early lung cancers have a 1% to 2% chance per
year of developing a new lung cancer.13 This means that
individuals alive 15 years after diagnosis have a cumulative
22.5% chance of developing a second primary lung cancer.
Although many of these new lung cancers are discovered
early, this could negatively affect the long-term survival.
A recent publication regarding curative resections for stage
I NSCLC details an early hazard of recurrence in the first 2
years and a low level of constant recurrence up to 14 yearsThe Journal of Thoracic and Carafter resection that may represent metachronous primary
cancers.14
Nodal stage had a significant impact on both OS and
DSS, but in a nonlinear manner, with the worst HRs seen
in patients with N1 disease (Tables 3 and 5). Patients with
N2 and N3 disease had progressively better OS and DSS.
The reasons for this are not clear but may reflect the high
degree of pathologic confirmation of N1 disease (typically
determined at operation only) as opposed to the relatively
more common non-pathologic determination of N2 or N3
(supraclavicular or contralateral tracheal) nodal disease.
Beyond 5 years, N2 and N3 disease do not seem to carry
the same negative prognostic survival value as they do at
5 years. Nodal positivity continues to affect the likelihood
of death 10, 15, and 18 years after initial diagnosis and treat-
ment. Tumor stage also had a significant impact on both OS
and DSS, although no significant differences were necessar-
ily seen between tumor stages above T1.
Tumor histology had a significant impact on long-term
survival. The category labeled as ‘‘other’’ in the SEER da-
tabase had an HR of 0.494 (P<.0001) for OS and 0.250
(P< .0001) for DSS. Although not specifically analyzed
in this study, a large number of these cancers were un-
doubtedly carcinoid tumors. In a prior study limited by
small sample size, Wada and colleagues3 demonstrated
significance for age, N-stage, and complete versus incom-
plete surgical resections in predicting survival after 5
years, but they did not find a significant difference between
adenocarcinoma compared with squamous cell carcino-
mas.5 The Lung Cancer Study Group published a report
that a disease-free survival advantage was seen with squa-
mous cell carcinomas up to 5 years after surgery, but no
survival advantage was seen after 5 years.15 Again, there
was a small sample size of only 21 patients who were alive
after 5 years. In our study, squamous cell cancers had
a highly statistically significant negative effect on overall
long-term survival relative to adenocarcinoma (HR,
1.082; P ¼ .0002) but a statistically significant positive
effect on long-term DSS (HR, 0.877; P ¼ .0001). This
may be related to a higher associated incidence of comor-
bid disease in those with squamous cell cancer because this
specific histologic subtype of NSCLS is more frequently
associated with a history of smoking. The improved
DSS of squamous cell carcinoma may indicate an inher-
ently lower risk of metastatic spread compared with
adenocarcinoma.
Age had an effect on both OS (HR, 1.045; P<.0001) and
DSS (HR, 1.021; P<.0001). There is an approximately 5%
increased risk of death for every increase in year of age in
regard to OS, whereas there is a 2% increased risk of death
from lung cancer for every increase in year of age after sur-
viving 5 years from the initial diagnosis of NSCLC. Increas-
ing age may influence the ability of an individual to survive
complications of lung cancer, thus influencing DSS. Malediovascular Surgery c Volume 143, Number 6 1311
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FIGURE 2. Graphs of 5- to 18-year DSS by surgery type. Survival is best in patients undergoing lobectomy or pneumonectomy.
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Sgender had a similar negative effect on OS (HR, 1.166;
P<.0001), but the DSS difference did not reach statistical
significance (HR, 1.054; P ¼ .053).TABLE 5. Analysis of disease-specific survival by competing risks Cox pr
Factor Parameter estimate SE
Age (per year increase) 0.020 0.00
Sex (male vs female) 0.053 0.02
Histology
Other vs adeno 1.587 0.10
Adenosquamous vs adeno 0.136 0.09
Large cell vs adeno 0.215 0.05
Squamous vs adeno 0.132 0.03
Unknown vs adeno 0.234 0.05
Surgery type
Pneumonectomy vs no surgery 0.821 0.06
Sublobectomy vs no surgery 0.342 0.06
Lobectomy vs no surgery 0.746 0.04
Site of tumor
4, 9 (bilateral, paired) vs right 0.028 0.02
Left vs right 0.325 0.15
T stage
T2 vs T1 0.106 0.03
T3 vs T1 0.255 0.06
T4 vs T1 0.2 0.05
Tunk vs T1 0.005 0.10
N stage
N1 vs N0 0.474 0.04
N2 vs N0 0.381 0.04
N3 vs N0 0.292 0.10
Nunk vs N0 0.084 0.08
M stage
M1 vs M0 0.313 0.06
Race
Black vs white 0.106 0.04
Other vs white 0.079 0.05
SE, Standard error; HR, hazard ratio.
1312 The Journal of Thoracic and Cardiovascular SurPneumonectomy and lobectomy carry a significant ad-
vantage in regard to both prolonged OS and DSS. Comor-
bidities are not measured in the SEER database and canoportional hazards model (multivariable regression)
HR 95% HR confidence limit P value
1 1.021 (1.018–1.023) <.0001
7 1.054 (0.999–1.113) .053
4 0.205 (0.167–0.251) <.0001
2 0.873 (0.729–1.045) .139
4 0.807 (0.725–0.898) <.0001
3 0.877 (0.822–0.935) <.0001
7 0.791 (0.708–0.885) <.0001
8 0.440 (0.385–0.503) <.0001
0 0.710 (0.631–0.799) <.0001
6 0.474 (0.433–0.519) <.0001
7 1.028 (0.975–1.085) .305
5 0.723 (0.534–0.979) .036
0 1.111 (1.047–1.180) .0005
9 1.290 (1.127–1.476) .0002
7 1.221 (1.092–1.366) .0005
7 0.995 (0.806–1.227) .96
2 1.607 (1.480–1.744) <.0001
7 1.464 (1.335–1.606) <.0001
4 1.339 (1.092–1.640) .005
4 1.088 (0.923–1.283) .316
9 1.367 (1.195–1.564) <.0001
6 1.112 (1.017–1.216) .020
5 0.924 (0.830–1.028) .148
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Sinfluence OS and perhaps, to a lesser degree, DSS. Patients
with borderline lung function or other significant comorbid-
ities are often preferentially offered lesser resections than fit
patients, and this may confound these findings. The persis-
tence and magnitude of the survival benefit in DSS for lobar
and greater surgical resection compared with sublobar re-
section suggest that factors other than comorbidities may
account for this advantage. In the absence of a prospective
randomized trial, definitive conclusions cannot be made in
regard to the effect of magnitude of resection on long-
term survival. In one of the few such trials conducted to
date, the Lung Cancer Study Group showed no statistically
significant difference in 5-year survival for stage I lung can-
cers treated with lobectomy versus sublobar resection.16
The finding that a left-sided cancer conferred a 38% bet-
ter disease-free long-term survival has not been described in
regard to long-term survival. It is well established that right-
sided pneumonectomy has a slightly higher mortality than
left-sided pneumonectomy.17 In regard to long-term sur-
vival, it is conceivable that patients who have had larger
lung resections (in right vs left pneumonectomy, the right
lung typically contributes 60% of total lung function)
may be at higher risk of late pneumonia and respiratory
death. Only 7% of patients in this study underwent
pneumonectomy.
CONCLUSIONS
The finding that many patients die of lung cancer well be-
yond the point at which many clinicians have considered
these patients ‘‘cured’’ (ie, 5 years) has not only obvious im-
plications for prognosis but also implications in regard to
treatment and clinical trial design. The concept of mainte-
nance chemotherapy for NSCLC is being explored as
newer, less toxic agents are developed.18 The finding that
lung cancer deaths occur far beyond 5 years suggests that
there may be significant benefit for long-term survivors if
such an agent can be found. In addition, it has recently be-
come apparent, as a result of long-term follow-up after ad-
juvant chemotherapy for resected NSCLC, that there may
be a loss in the survival benefit of chemotherapy with pro-
longed survival.19 In the long-term follow up (median 90
months) publication of the International Adjuvant Lung
Cancer Trial, the survival benefit to adjuvant chemotherapy
was lost in delayed follow-up. The HR for death after che-
motherapy was 0.86 (P ¼ .01) for the first 5 years, but 1.45
(P ¼ .04) after 5 years. There is concern that some of these
late deaths may be from delayed chemotoxicity. A certain
percentage of these deaths, however, may likely be delayedThe Journal of Thoracic and Carcancer deaths that are seen even without chemotherapy.
This evolving concept that a significant number of cancer
deaths occur well beyond 5 years should be incorporated
into future trials.
The authors thank Julie Worthington, PhD, for statistical analy-
ses and contributions to the article.
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